openPR Logo
Press release

Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Size, Key Drivers, Growth ,Analysis 2024-2033

09-26-2024 06:12 AM CET | Health & Medicine

Press release from: The Business research company

Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Size

Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Size

The Business Research Company recently released a comprehensive report on the Global Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.

According to The Business Research Company's, The hereditary breast and ovarian cancer syndrome treatment market size has grown strongly in recent years. It will grow from $6.28 billion in 2023 to $6.72 billion in 2024 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to increased awareness and screening, supportive government policies, patient advocacy and empowerment, collaboration in research.

The hereditary breast and ovarian cancer syndrome treatment market size is expected to see strong growth in the next few years. It will grow to $8.57 billion in 2028 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to growing role of artificial intelligence, expanded access to genetic counseling, regulatory approvals for targeted therapie, personalized treatment plans, international collaborations in research. Major trends in the forecast period include gene editing technologies, advancements in immunotherapy, technological advances in oncology, immunotherapy for brca-related cancers, comprehensive multidisciplinary care.

Get The Complete Scope Of The Report @
https://www.thebusinessresearchcompany.com/report/hereditary-breast-and-ovarian-cancer-syndrome-treatment-global-market-report

Market Drivers and Trends:

The rise in genetic disorders is expected to propel the growth of the hereditary breast and ovarian cancer syndrome treatment market going forward. Newborn screening is a physical examination that screens all babies shortly after birth for specific health conditions, which health professionals use to identify and treat specific requirements before they make a baby sick. Newborn screening could identify babies at high risk of developing breast cancer and ovarian cancer, allowing them to start preventive measures early. For instance, in 2022, according to the Texas Department of State Health Services, a US-based state health agency, the total specimens received for newborn screening increased by 4.3% from 729,347 in 2021 to 761,000 in 2022. Further, around 394,000 babies were screened, and 1,130 babies were affected by one of the NBS disorders in 2022. Therefore, the rise in genetic disorders is driving the growth of the hereditary breast and ovarian cancer syndrome treatment market.

Major companies operating in the hereditary breast and ovarian cancer syndrome treatment market are adopting new treatment options, such as comprehensive risk tests, to provide reliable services to the customers. A complete risk assessment test is a tool that helps to identify an individual's risk of developing a disorder or experiencing a symptom of a disease. For instance, in February 2023, Genetic Technologies Limited, an Australia-based molecular diagnostics company, launched a ground-breaking comprehensive risk assessment test, a type of treatment for breast and ovarian cancer. It combines gene mutation testing for breast and ovarian cancers, hereditary and non-hereditary risk factors, and the GeneType risk score for both cancers. It has a unique approach that combines the detection of the 13 primary actionable breast and ovarian cancer susceptibility genes with the GeneType test platform. The new test platform addresses women over 30 who, outside of unusual genetic alterations, are at higher risk of developing breast and ovarian cancer in the general population.

Key Benefits for Stakeholders:

• Comprehensive Market Insights: Stakeholders gain access to detailed market statistics, trends, and analyses that help them understand the current and future landscape of their industry.
• Informed Decision-Making: The reports provide crucial data that support strategic decisions, reducing risks and enhancing business planning.
• Competitive Advantage: With in-depth competitor analysis and market share information, stakeholders can identify opportunities to outperform their competition.
• Tailored Solutions: The Business Research Company offers customized reports that address specific needs, ensuring stakeholders receive relevant and actionable insights.
• Global Perspective: The reports cover various regions and markets, providing a broad view that helps stakeholders expand and operate successfully on a global scale.

Ready to Dive into Something Exciting? Get Your Free Exclusive Sample of Our Research Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=13209&type=smp

Major Key Players of the Market:

Major companies operating in the hereditary breast and ovarian cancer syndrome treatment market report are Pfizer Inc., Johnson & Johnson Private Limited, F. Hoffmann-La Roche Ltd., Merck & Co., AbbVie Inc., Bayer AG, Sanofi-Aventis LLC , AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Co. Ltd., Vertex Pharmaceuticals Inc., Mercy Health, Hikma Pharmaceuticals plc, Amneal Pharmaceuticals LLC, Lupin Limited , Seagen Inc., LEO Pharma Inc., LifeLabs Genetics, Natera Inc., Fresenius Kabi AG, Myriad Genetics Inc., Invitae Corporation, Editas Medicine Inc., GenMark Diagnostics Inc., Genentech Inc., CRISPR Therapeutics AG, Advocate Health Care

Hereditary Breast and Ovarian Cancer Syndrome Treatment Market 2024 Key Insights:

• The hereditary breast and ovarian cancer syndrome treatment market is expected to grow to $8.57 billion in 2028 at a compound annual growth rate (CAGR) of 6.3%.
• Genetic Disorders Driving Growth In Hereditary Breast And Ovarian Cancer Syndrome Treatment Market
• Innovative Treatment Approaches In The Hereditary Breast And Ovarian Cancer Syndrome Market
• North America was the largest region in the hereditary breast and ovarian cancer syndrome treatment market in 2023

We Offer Customized Report, Click @
https://www.thebusinessresearchcompany.com/Customise?id=13209&type=smp

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Size, Key Drivers, Growth ,Analysis 2024-2033 here

News-ID: 3668175 • Views:

More Releases from The Business research company

Top Players and Competitive Dynamics in the Rocket Capsule Recovery Market
Top Players and Competitive Dynamics in the Rocket Capsule Recovery Market
Exploring the Future of the Rocket Capsule Recovery Market The rocket capsule recovery market is set to experience substantial expansion over the coming years. Driven by technological advancements and increasing commercial space activities, this industry is poised for significant growth by 2030. Let's delve into the market size projections, key players, emerging trends, and segment details that shape this evolving sector. Projected Market Size and Growth Trajectory of the Rocket Capsule
Analysis of Segmentation, Market Dynamics, and Competitive Landscape in the Robotic Arm for Space Market
Analysis of Segmentation, Market Dynamics, and Competitive Landscape in the Robo …
The robotic arm technology designed for space applications is rapidly advancing, driven by increasing demand for sophisticated operations beyond Earth's atmosphere. As space missions become more complex, the need for precise, autonomous robotic arms is growing, opening new avenues for satellite servicing, construction, and maintenance in orbit. Here's an in-depth look at the market size, key players, emerging trends, and segmentations shaping the future of robotic arms for space. Robotic Arm
Leading Companies Advancing Innovation and Growth in the Reusable Rocket Market
Leading Companies Advancing Innovation and Growth in the Reusable Rocket Market
The reusable rocket market is gaining remarkable momentum as innovations and growing commercial interest drive its expansion. With increasing adoption by satellite operators and advances in technology, this sector is set to experience substantial growth by 2030. Let's explore the current market size, key players, emerging trends, and how the industry is shaping up for the future. Projected Market Growth for Reusable Rockets by 2030 The reusable rocket market is anticipated
Analysis of Segments and Major Growth Areas in the Rapid Prototyping Market for Aerospace and Defense
Analysis of Segments and Major Growth Areas in the Rapid Prototyping Market for …
The aerospace and defense sectors are increasingly relying on rapid prototyping technologies to accelerate innovation and improve efficiency. This market is gaining momentum, driven by advancements in manufacturing methods and growing demands for high-precision components. Let's explore the current market valuation, key players, emerging trends, and major segments shaping the rapid prototyping industry within aerospace and defense. Projected Market Growth and Size in Rapid Prototyping for Aerospace and Defense The rapid

All 5 Releases


More Releases for Hereditary

Unraveling Hereditary Cancer With The Rising Demand For Hereditary Cancer Testin …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. What Will the Hereditary Cancer Testing Industry Market Size Be by 2025? The market encompassing hereditary cancer testing has exhibited robust expansion throughout the recent past, projecting an increase from its value of $4.32 billion in 2024 to reach $4.75 billion for the subsequent year, reflecting a consistent annual
Leber Hereditary Optic Neuropathy Treatment Market
Introduction Leber Hereditary Optic Neuropathy (LHON) is a genetic condition that leads to severe vision loss, primarily affecting young adults. This disorder is caused by mutations in mitochondrial DNA, which impairs the function of retinal ganglion cells. As awareness of LHON has grown, so too has the focus on its treatment options. The LHON treatment market is evolving rapidly, driven by advancements in genetic therapies, pharmaceuticals, and supportive care strategies. This
Hereditary Hemochromatosis Market - Redefining Care, Inspiring Hope: Hereditary …
Newark, New Castle, USA: The "Hereditary Hemochromatosis Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors. Hereditary Hemochromatosis Market: https://www.growthplusreports.com/report/hereditary-hemochromatosis-market/8793 This latest report researches the industry structure, sales, revenue,
Hereditary Angioedema Market Research Report 2032
DelveInsight's "Hereditary Angioedema Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the Hereditary Angioedema, historical and forecasted epidemiology as well as the Hereditary Angioedema market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Hereditary Angioedema (HAE) is a rare genetic disorder caused by the deficiency in functional C1 inhibitor (C1INH) that results in recurrent attacks of localized subcutaneous or
Hereditary Angioedema - Drug Pipeline Landscape, 2022
Global Hereditary Angioedema Market report from Global Insight Services is the single authoritative source of intelligence on hereditary angioedema market. The report will provide you with analysis of impact of latest market disruptions such as Russia-Ukraine war and Covid-19 on the market. Report provides qualitative analysis of the market using various frameworks such as Porters' and PESTLE analysis. Report includes in-depth segmentation and market size data by categories, product types,
Hereditary Angioedema - Drug Pipeline Landscape, 2022
Hereditary Angioedema is an infrequent inherited disease that causes substantial swelling in various body tissues, such as the abdomen or face caused by a low level or improper function of a protein called the C1 inhibitor. There are three types of hereditary angioedema namely type I, II, and III. Hereditary Angioedema is mainly caused by a low level or improper function of a protein called the C1 inhibitor. Read more about Hereditary